Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

TD Cowen projects that with Eli Lilly (NYSE ... semaglutide will be competing neck and neck in the GLP-1 market in 2030 with their products, Mounjaro/ Zepbound and Ozempic/ Wegovy, respectively.

Eli Lilly pulled in revenues of $45 billion in 2024. $11.5 billion of this was driven by Mounjaro, with sales of the GLP-1 drug growing 124% year-on-year.

Eli Lilly and Company (India) has launched 'Mounjaro,' a novel medication for obesity and type 2 diabetes, after receiving ...

This is given that its GLP-1 therapies, including Mounjaro and Zepbound ... receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose ...

Feb 20 - Eli Lilly (LLY, Financial) is set to pivot its focus beyond obesity after a monumental windfall from its GLP-1 drugs. At its February monthly ... Buoyed by transformative products like ...

Eli Lilly is growing faster with Zepbound and Mounjaro, as the active ingredient ... Lilly’s chances of leading the GLP-1 race long-term are higher, but investors should brace for volatility ...

On Wednesday, a federal judge ruled that compounding pharmacies must stop selling versions of Eli Lilly's Zepbound and Mounjaro ... an interview request. As GLP-1 drugs have gotten more popular ...

These are some of the areas where Eli Lilly, flush with cash from its GLP-1 drugs, wants to make big ... Lilly's tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, has ...

Lilly figures it won't have to be conservative with launch supplies of orforglipron, unlike the situation with Mounjaro and Zebpound. For its injectable GLP-1s, which were met with immense ...